title: Prolonged skin allograft survival by IL-10 gene-introduced CD4 T cell administration.
abstract: Both CD4 and CD8 T cells play crucial roles in immune responses in transplantation. Immunosuppressive drugs, such as FK506 and cyclosporin A, block the priming of alloreactive CD4 T(h) cells and the subsequent induction of allospecific CD8 cytotoxic effector T cells and inhibit allograft rejection. However, the desire to minimize chronic complications that may arise from the use of immunosuppressive agents drives the search for additional strategies for immunosuppression of allograft rejection. In this study, CD4 or CD8 T cells into which the IL-10 gene is introduced using an adenovirus vector containing human IL-10 (hIL-10) cDNA (Ad-hIL-10) and into mouse T cells transgenic for the Coxsackie virus and adenovirus receptor form a model system to study the effect of administration of IL-10-secreting T cells on the survival of the allogenic skin grafts. Ad-hIL-10-infected CD4 and CD8 T cells secreted a large amount of hIL-10 for 3-4 days in culture in vitro. Ad-hIL-10-infected CD4 T cells administered in vivo could be detected in the spleen for 7 days post-transfer. Significantly prolonged survival of grafts was observed in animals that received either Ad-hIL-10-infected activated CD4 T cells or T(h)2-skewed CD4 T cells as compared with controls. Furthermore, substantial enhancement of the effect was observed in B6.C-H2(bm1)/ByJ transplants. Thus, a direct manipulation of T cells through the introduction of the immunosuppressive cytokine gene IL-10 may be a novel strategy for the control of allograft rejection.
authors.affiliation: Department of Immunology, Chiba University, Chuo-ku, Chiba 260-8670, Japan.
authors.forename: Takeshi
authors.initials: T
authors.lastname: Miyamoto
authors.forename: Takaaki
authors.initials: T
authors.lastname: Kaneko
authors.forename: Masakatsu
authors.initials: M
authors.lastname: Yamashita
authors.forename: Yoshiyuki
authors.initials: Y
authors.lastname: Tenda
authors.forename: Masamichi
authors.initials: M
authors.lastname: Inami
authors.forename: Akane
authors.initials: A
authors.lastname: Suzuki
authors.forename: Sohtaro
authors.initials: S
authors.lastname: Ishii
authors.forename: Motoko
authors.initials: M
authors.lastname: Kimura
authors.forename: Kahoko
authors.initials: K
authors.lastname: Hashimoto
authors.forename: Hideaki
authors.initials: H
authors.lastname: Shimada
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Yahata
authors.forename: Takenori
authors.initials: T
authors.lastname: Ochiai
authors.forename: Izumu
authors.initials: I
authors.lastname: Saito
authors.forename: James
authors.initials: J
authors.lastname: DeGregori
authors.forename: Toshinori
authors.initials: T
authors.lastname: Nakayama
mesh_terms: D000256:Adenoviridae; D000818:Animals; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology*; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology*; D004770:Enterovirus / Q000235:genetics; D018014:Gene Transfer Techniques; D006085:Graft Survival / Q000276:immunology*; D007165:Immunosuppression Therapy; D016753:Interleukin-10 / Q000096:biosynthesis* / Q000235:genetics / Q000276:immunology; D008213:Lymphocyte Activation; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D008822:Mice, Transgenic; D016038:Skin Transplantation / Q000276:immunology*; D013154:Spleen / Q000166:cytology / Q000276:immunology; D016176:T-Lymphocyte Subsets / Q000276:immunology*; D016559:Tacrolimus / Q000494:pharmacology; D018418:Th2 Cells / Q000276:immunology
chemical_list: D016753:Interleukin-10; D016559:Tacrolimus